Primary care capacity. The HMO Group Conference.
Explore the source record for details and available documents.
Health Maintenance Organizations↗
Biomedical subjects
C F Koller
Publications and source records attributed to C F Koller.
Provider contracting workshop.
Explore the source record for details and available documents.
Contract Services↗
Technology management information exchange (TEMINEX). Applied technology assessment for HMOs.
In an effort to obtain timely, comprehensive and valid information, The HMO Group medical directors have pooled resources to facilitate decision-making on the appropriate use of new or unfamiliar technologies. The HMO Group has responded to over 175 requests for information on topics such as organ transplants, testing and screening procedures, drugs and devices.
Health Maintenance Organizations↗
State health insurance pools: current performance, future prospects.
State health insurance pools have been suggested to help cover the uninsured. Their attraction lies in the theoretical economies of pooling and the limited public role intended for their administration and funding. Almost all existing pools have targeted high health risks, otherwise uninsurable people who can still afford high premiums for conventional, major-medical-style coverage. Enrollments have been low, even relative to the small eligible population, and medical spending high. Little risk pooling or other savings seem to have occurred. Deficits have therefore mounted, necessitating increased assessments on all private health insurers in pool states and indirectly burdening state treasuries as well. Better pools would have to attract a broader mix of risks, actively manage medical spending, or both.
Adult↗
The role of glycoprotein IIb/IIIa inhibition in the management of acute coronary syndromes.
Recent advances in the understanding of the pathophysiology of thrombus formation and the role of platelet adhesion have led to a new pharmacologic era in cardiology. The advent of the glycoprotein IIb/IIIa inhibitor, primarily used in conjunction with percutaneous coronary intervention, has proved to be beneficial beyond the confines of the cardiac catheterization laboratory. The glycoprotein IIb/IIIa inhibitor has inspired much research in the past few years of its use in the management of acute coronary syndromes. The CAPTURE, PURSUIT, PRISM, and PRISM-PLUS trials have all documented the beneficial effects of glycoprotein IIb/IIIa inhibition that have reduced 2 of the major sequelae of acute coronary syndromes: myocardial infarction and death. Through the implementation of primary research-based data, it is the job of practitioners to appropriately stratify and implement judicious use of glycoprotein IIb/IIIa inhibition with the population affected by acute coronary syndromes.
Abciximab↗